RxDoctor Payments Data

Richard Moore, MD

Internal Medicine · Vero Beach, FLNPI 1376518142

Payments from drug & device makers

$1,554in general payments, 2019–2025

Across 23 payments — averaging $67.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$449
  • Boston Scientific$306
  • AstraZeneca$254
  • Pfizer$149
  • Novartis$136
  • Inspire Medical Systems, Inc.$102
  • plus $156 from 4 others

What the payments were for

  • Food & beverage$1,53299%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,554 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$115,295
Medicare patients
1,446
Services billed
2,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$293,590
JardianceEmpagliflozin53$57,520
EntrestoSacubitril/Valsartan27$38,393
XareltoRivaroxaban25$23,061
BrilintaTicagrelor34$21,880
Midodrine Hcl15$4,884
Diltiazem 24hr Er (Cd)Diltiazem Hcl87$2,850
Metoprolol Succinate219$2,847
Ranolazine ErRanolazine26$2,615
Atorvastatin Calcium285$2,402
Ezetimibe73$1,830
Rosuvastatin Calcium158$1,700
Valsartan91$1,661
Flecainide Acetate41$1,438
ClopidogrelClopidogrel Bisulfate95$1,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$149$293,590293 claims
Boehringer IngelheimJardiance$13$57,52053 claims
NovartisEntresto$136$38,39327 claims
Johnson & JohnsonXarelto$93$23,06125 claims
AstraZenecaBrilinta$254$21,88034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →